Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719173 · ClinicalTrials.gov registry record · Phase 1
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
A Phase 1 study of Breast Cancer and Nausea and Vomiting, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00719173: Completed Phase 1 study of Breast Cancer and Nausea and Vomiting, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT00719173 is a Phase 1 study of Breast Cancer and Nausea and Vomiting that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 19 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00719173, a Phase 1 study of Breast Cancer and Nausea and Vomiting, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing chemotherapy for breast cancer.
Primary Outcome
Cyclophosphamide, 4-OH cyclophosphamide, and DCE PK with and without aprepitant
Conditions Studied
Interventions
- OTHER placebo
- DRUG cyclophosphamide
- DRUG aprepitant
Study Locations (1)
North Carolina
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
What the finished NCT00719173 record still lists
NCT00719173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00719173 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00719173 about?
NCT00719173 is a clinical study titled "Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer". RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing c...
What is the current status of trial NCT00719173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-08. Estimated completion is 2010-10.
What conditions does trial NCT00719173 study?
This clinical trial studies the following conditions: Breast Cancer, Nausea and Vomiting.
What interventions are being tested in trial NCT00719173?
The interventions under investigation include: placebo (OTHER), cyclophosphamide (DRUG), aprepitant (DRUG).
Who is sponsoring clinical trial NCT00719173?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00719173 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00719173's enrollment target sits among peer trials
19 1114th of 1224 higher than 108 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia